Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients
Cihan TaŞtanDerya Dilek KançağıRaife Dilek TuranBulut YurtseverDidem ÇakirsoySelen AbanuzMuhammet YılancıUtku SeyisSamed ÖzerSelin MertCavit Kerem KayhanFatma TokatMerve Açıkel ElmasSelçuk BİrdoĞanSerap ArbakKoray YalçınAslıhan SezginEbru KızılkılıçCansu HemşinlioğluÜmit İnceSiret RatipErcüment OvalıPublished in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2020)
This is the first report of preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B cells in relapsed/refractory ALL and NHL patients in Turkey.
Keyphrases
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- acute lymphoblastic leukemia
- acute myeloid leukemia
- peritoneal dialysis
- diffuse large b cell lymphoma
- induced apoptosis
- cell death
- patient reported outcomes
- cancer therapy
- mesenchymal stem cells
- bone marrow
- cell cycle arrest
- signaling pathway
- study protocol
- medical students
- clinical evaluation